Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Article 1997 en
Authors
SO
Steven M. Opal
CF
Charles J. Fisher
JD
Jean-François Dhainaut
Abstract
1 min read
A 72-hr, continuous intravenous infusion of rhIL-1ra failed to demonstrate a statistically significant reduction in mortality when compared with standard therapy in this multicenter clinical trial. If rhIL-1ra treatment has any therapeutic activity in severe sepsis, the incremental benefits are small and will be difficult to demonstrate in a patient population as defined by this clinical trial.
Yupin Suputtamongkol, Sunanta Intaranongpai, Michael D. Smith, Brian Angus, Wipada Chaowagul, Chairat Permpikul, J. A. Simpson, Amorn Leelarasamee, Lloyd Curtis, Sir Nicholas White
R. Phillip Dellinger, Jean Carlet, Henry Masur, Herwig Gerlach, Thierry Calandra, Jonathan Cohen, Juan Gea‐Banacloche, Didier Keh, John C. Marshall, Margaret M. Parker, Graham Ramsay, Janice L. Zimmerman, Jean Louis Vincent, Mitchell M. Levy
Discussion(0)
No comments yet. Be the first to comment.